Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY
Tieton Capital Management LLC has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the second quarter, purchasing 306,781 shares valued at approximately $11.17 million. This investment makes Harmony Biosciences the 16th largest holding in Tieton Capital Management LLC's portfolio, representing 3.2% of its total assets. Other institutional investors have also adjusted their stakes in Harmony Biosciences, and the company has received mixed analyst ratings with an average "Hold" rating and a price target of $45.50.
Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY
Denali Advisors LLC has significantly increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by purchasing an additional 29,700 shares, bringing its total holdings to 89,600 shares valued at approximately $3.26 million. This move comes as Harmony Biosciences reported strong quarterly earnings, surpassing analyst expectations with $1.28 EPS and $261.28 million in revenue. Despite a consensus "Hold" rating from analysts, the company's stock shows positive momentum, with institutional investors collectively owning a substantial 86.23% of the company.
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY
Aurora Investment Counsel has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), purchasing 65,148 shares valued at approximately $2.37 million, making it their 22nd largest holding. Other institutional investors have also adjusted their stakes in Harmony Biosciences. The company's stock recently increased by 2.8%, and analysts have issued various ratings, with the consensus being a "Hold" with a target price of $45.50.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Hold" by Analysts
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has received a consensus "Hold" rating from ten analysts, with an average 12-month price target of $45.50. The company recently surpassed earnings and revenue expectations, reporting $1.28 adjusted EPS against an estimated $0.96 and a 30.3% year-over-year revenue increase to $261.28 million. Institutional investors hold a significant 86.23% stake in HRMY, with several firms increasing their positions.
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative?
Harmony Biosciences (HRMY) reported strong Q2 2026 earnings, with net income of US$75.43 million and diluted EPS of US$1.28, and completed a US$50 million share repurchase program. While these results reinforce the company's profitability, the core investment narrative remains largely unchanged, with a continued reliance on its flagship drug WAKIX and the need for pipeline diversification. The earnings beat may lead analysts to reassess more pessimistic revenue and earnings forecasts, and the company projects significant revenue and earnings growth by 2028.
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative?
Harmony Biosciences (HRMY) reported strong Q2 2026 earnings, with net income of US$75.43 million and diluted EPS of US$1.28, and completed a US$50 million share repurchase program. While this reinforces the company's profitability, its investment narrative still hinges on broadening beyond its flagship drug WAKIX and mitigating the risk of concentration on a single product. Forecasts project significant revenue and earnings growth by 2028, suggesting a potential 24% upside from its current price.
Chase Investment Counsel Corp Takes $1.82 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
Chase Investment Counsel Corp has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), purchasing 50,000 shares valued at approximately $1.82 million, representing a 0.09% stake. Harmony Biosciences reported strong quarterly earnings of $1.28 per share, exceeding estimates, with revenue increasing by 30.3% year over year. Despite mixed analyst ratings, with an average "Hold" and a price target of $45.50, the company's stock shows solid financial metrics and institutional ownership.
Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, the broader analyst consensus for HRMY remains a "hold" with an average target price of $45.50.
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences reported record quarterly performance for its narcolepsy treatment WAKIX, supporting further investment in its pipeline. The company provided updates on its orexin 2 receptor agonist BP-205 for narcolepsy and other CNS indications, and EPX-100 (clemizole hydrochloride) for Dravet and Lennox-Gastaut syndromes, with key data readouts and potential approvals expected in the coming years. Additionally, Harmony outlined plans for new formulations of pitolisant (WAKIX), including a gastro-resistant version and a higher-dose option, aiming to expand treatment options and market exclusivity.
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase III trials for EPX-100 in Dravet and Lennox-Gastaut syndromes, and developing new pitolisant formulations to expand treatment options for narcolepsy and idiopathic hypersomnia.
Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold
Zacks Research has downgraded Harmony Biosciences (NASDAQ:HRMY) from a "strong buy" to a "hold" rating, aligning with the overall consensus. Despite the downgrade, Harmony Biosciences reported a strong quarter with EPS of $1.28 and revenue of $261.28 million, exceeding analyst expectations. The stock opened at $39.77, near its 52-week high, and institutional investors hold a significant 86.23% stake in the company.
Why Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Surge And Pipeline Progress
Harmony Biosciences (HRMY) saw its stock rise by 9.0% following a strong Q2 2026 earnings report, with net income and EPS significantly increasing year-over-year. The company reaffirmed its 2026 net product revenue guidance, indicating confidence in its lead drug WAKIX while it continues to advance its neurology pipeline. Despite the positive results, the article highlights the ongoing concentration risk associated with WAKIX and the need for pipeline diversification.
Why Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Surge And Pipeline Progress
Harmony Biosciences reported a significant 9.0% stock increase after its Q2 2026 earnings surged to US$75.43 million, with basic EPS rising to US$1.30. This strong performance, alongside pipeline progress in rare neurological diseases, reinforces the company's near-term outlook and its reliance on WAKIX revenue while its new therapies mature. The company reiterated its 2026 net product revenue guidance of US$1.0 billion to US$1.04 billion, prompting investors to consider the balance between current cash generation and the concentration risk around its primary drug.
Harmony Biosciences (NASDAQ:HRMY) Upgraded by Wall Street Zen to "Buy" Rating
Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "hold" to a "buy" rating. The company recently reported strong quarterly earnings of $1.28 per share, surpassing estimates, with revenue increasing by 30.3% year-over-year to $261.28 million. Institutional investors hold a significant 86.23% of the shares, with BlackRock Inc. notably establishing a new position worth approximately $258.6 million.
First Trust Advisors LP Sells 50,805 Shares of Harmony Biosciences Holdings, Inc. $HRMY
First Trust Advisors LP reduced its stake in Harmony Biosciences Holdings, Inc. by 32.7% during the first quarter, selling 50,805 shares and retaining 104,549 shares valued at approximately $2.93 million. Harmony Biosciences reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite varied analyst ratings, the company holds a "Moderate Buy" consensus with an average price target of $45.50.
Harmony Biosciences Holdings (HRMY) Could Be 19% Undervalued On Strong Q2 Earnings
Harmony Biosciences Holdings (HRMY) has shown strong performance following its Q2 2026 earnings, with increased net income and EPS, supported by WAKIX and pipeline updates. The company's share price has gained significantly over the past 90 days, and a valuation narrative suggests it is 19.2% undervalued, with a fair value of $47.30 per share. This positive outlook is driven by anticipated faster earnings growth, higher profitability, and a promising late-stage pipeline including potential first-to-market launches.
Harmony Biosciences (NASDAQ: HRMY) holder to sell 700,883 shares
VALOR IV PHARMA HOLDINGS LLC, a shareholder of Harmony Biosciences (NASDAQ: HRMY), has filed to sell up to 700,883 shares of common stock. These shares, with an aggregate market value of $26,563,465.70, were originally acquired in 2017 through a private acquisition. The filing also notes prior sales by the same holder totaling 116,490 shares for approximately $4.3 million over the past three months.
Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline Progress - What's Changed
Harmony Biosciences (HRMY) reported a significant increase in Q2 2026 net income, rising to US$75.43 million from US$39.78 million a year prior, with EPS increasing to US$1.30. The company also announced progress in its neurology pipeline and clinical trials, which strengthens its investment narrative by balancing current cash-generating products with long-term development assets. While the earnings jump is positive, the company's heavy reliance on its drug WAKIX remains a key risk for investors.
Harmony Biosciences Holdings, Inc. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported a significant 34% EPS beat for its second quarter, with revenue also exceeding expectations. Analysts have revised their future earnings estimates upwards, projecting robust growth in the coming years. Despite these positive revisions, there are concerns regarding the company's P/E ratio relative to its industry and the broader market.
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
Harmony Biosciences will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A webcast of the event will be available on the investor page of the company's website. Harmony Biosciences focuses on developing innovative therapies for rare neurological diseases.
Harmony Biosciences management plans Aug. 13 fireside chat webcast
Harmony Biosciences (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A live webcast will be accessible via the investor page of the Harmony Biosciences website. The company is focused on developing and commercializing therapies for patients with rare neurological diseases.
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM)
Two healthcare stocks, Harmony Biosciences Holdings (HRMY) and Beam Therapeutics (BEAM), have received bullish ratings from analysts. H.C. Wainwright reiterated a Buy rating for Harmony Biosciences with a $55.00 price target, while Beam Therapeutics holds a Strong Buy consensus with a target of $55.00, suggesting significant upside. These recommendations highlight analyst confidence in the future performance of these companies within the healthcare sector.
Harmony Biosciences Holdings, Inc. Stock 12‑Month Price Target Cut to $44.7, Implies 26% Upside
Harmony Biosciences Holdings, Inc.'s average 12-month stock price target has been reduced from $45.5 to $44.7 by 10 analysts, with individual forecasts ranging from $28 to $70 per share. This new target suggests a potential upside of approximately 26% based on the August 3rd closing price. Despite the target cut, the consensus rating from covering analysts remains a "Buy."
Harmony Biosciences (HRMY) Q2 2026 earnings summary
Harmony Biosciences (HRMY) reported record Q2 2026 net revenue of $261.3 million, a 30% increase year-over-year, driven by strong WAKIX demand. The company reiterated its full-year 2026 net revenue guidance of $1.0 billion to $1.04 billion and advanced its pipeline with positive Phase 1 data for BP-205 and other late-stage CNS programs. Harmony Biosciences maintains a robust pipeline with five phase III registration studies and significant liquidity.
Harmony Biosciences 2Q 2026: Revenue $261.28M, EPS $1.28— 10-Q Summary
Harmony Biosciences Holdings, Inc. reported strong second-quarter 2026 results, with revenue reaching $261.28 million and diluted EPS at $1.28, significantly up from the prior year. This growth was driven by increased product volume and a price adjustment in January 2026. The company also highlighted expanded formulary coverage, progress in its product pipeline with an NDA submitted for Pitolisant GR, and active IP and licensing efforts.
Harmony Biosciences Holdings, Inc. Q2 2026 Earnings Call Summary
Harmony Biosciences Holdings, Inc. reported record Q2 2026 net revenue of $261.3 million for WAKIX, a 30% year-over-year increase, and reaffirmed full-year guidance of $1 billion to $1.04 billion. The company highlighted promising Phase I data for its new orexin-2 receptor agonist, BP-205, with multiple catalysts expected, and detailed its strategic financial position with $962.5 million in cash for potential M&A. Operational challenges include increased cost of sales due to new royalty obligations and ongoing litigation with an ANDA filer, AET Pharma.
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer
Oppenheimer analyst Andreas Argyrides has lowered the price target for Harmony Biosciences Holdings Inc. (HRMY) to $70. This information was updated on August 4, 2026, at 2:30 PM EDT. The full details of this analyst action are available only to premium subscribers of StreetInsider.com.
Oppenheimer lowers Harmony Biosciences stock price target on model updates
Oppenheimer has lowered its price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) to $70 from $85, while maintaining an Outperform rating. This adjustment follows the company's strong second-quarter 2026 results, which saw Wakix net sales exceed estimates, and the reiteration of full-year 2026 guidance. The firm's model update also considers new Phase 1 data for BP-205 and upcoming intellectual property resolution for Wakix.
Harmony Biosciences Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HRMY)
Harmony Biosciences Holdings, Inc. released its Q2 2026 earnings, reporting an EPS of $1.50, which beat estimates by $0.35. The company's revenue reached $261.28 million, surpassing expectations by $8.01 million and showing a 30.32% year-over-year increase. This presentation accompanies their earnings call for the quarter.
Harmony Biosciences Holdings Surges 11.0% Amid Sector-Wide Rally
Harmony Biosciences Holdings (HRMY) surged 11.0% to $39.50, driven by a sector-wide rally in biotechnology stocks, with peers like AMLX and NUVB also seeing gains. The company's stock experienced elevated trading volume, adding to its market capitalization of $2.3 billion. Positive analyst sentiment, including a recent target raise, further supports the upward trajectory of Harmony Biosciences.
Harmony Biosciences (NASDAQ: HRMY) lifts Q2 profit as WAKIX sales grow
Harmony Biosciences (HRMY) reported a significant increase in Q2 2026 profitability, with net product revenue rising to $261.28 million and net income reaching $75.43 million, driven by strong WAKIX sales. The company's pipeline includes Pitolisant GR with a PDUFA date of April 1, 2027, and ongoing Phase 3 trials for other drug candidates. Harmony Biosciences also provided updates on its liquidity, legal proceedings regarding generic WAKIX, and key financial metrics from its latest 10-Q filing.
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) reported Q2 earnings of $1.28 per share, significantly beating the Zacks Consensus Estimate of $0.97, and revenues of $261.28 million, surpassing estimates by 3.46%. Despite underperforming the market year-to-date, the company holds a Zacks Rank #1 (Strong Buy) due to favorable earnings estimate revisions, suggesting potential market outperformance. The article also touches upon future earnings expectations for Harmony Biosciences and mentions a peer in the same industry, Alvotech (ALVO).
(HRMY) Harmony Biosciences Expects 2026 Wakix Net Revenue Range $1.0B to $1.04B
Harmony Biosciences Holdings, Inc. (HRMY) anticipates its 2026 net revenue from Wakix to be in the range of $1.0 billion to $1.04 billion. This announcement follows recent financial updates, including Q2 EPS of $1.28 and Q2 revenue of $261.3 million, both exceeding FactSet estimates. The company, which specializes in therapies for rare neurological diseases, reiterated its full-year 2026 earnings guidance.
Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Reports Q2 Revenue $261.3M, vs. FactSet Est of $250.8M
Harmony Biosciences Holdings, Inc. reported Q2 revenue of $261.3 million, surpassing FactSet's estimate of $250.8 million. The company, focused on therapies for rare neurological diseases, also announced its Q2 2026 earnings call and confirmed earnings results for the quarter and six months ended June 30, 2026. This financial update follows recent news regarding its Wakix net revenue projections and changes in its executive team.
Harmony Biosciences Announces Record Q2 2026 Revenue and
Harmony Biosciences reported record Q2 2026 revenue of $261.3 million for WAKIX, a 30% year-over-year increase, and reiterated its full-year guidance of $1.0 billion to $1.04 billion. The company also shared positive Phase 1 clinical data for its orexin-2 agonist BP-205, reinforcing its potential as a best-in-class treatment for various CNS indications, with Phase 2 trials expected to begin mid-2027. Additionally, Harmony Biosciences provided updates on its pipeline, including NDA acceptance for Pitolisant GR and ongoing trials for Pitolisant HD and WAKIX in PWS.
HRMY Maintained by Mizuho -- Price Target Raised to $51.00
Mizuho has maintained an "Outperform" rating for Harmony Biosciences Holdings (HRMY) and increased its price target to $51.00, reflecting optimism for the biotechnology company. HRMY is currently valued at $34.76, indicating a 26.5% undervaluation according to GuruFocus's GF Value™ of $47.30, and holds a strong GF Score™ of 94/100. This suggests potential growth for investors, especially given positive sentiment from institutional investors.
Mizuho Lifts Price Target on Harmony Biosciences Holdings to $51 From $50, Keeps Outperform Rating
Mizuho has increased its price target for Harmony Biosciences Holdings (HRMY) to $51 from $50, while reiterating an Outperform rating. This adjustment suggests a continued positive outlook on the company's stock performance.
Harmony Biosciences Holdings Inc (HRMY) Valuation: PE, PB & Fair Value Analysis
Harmony Biosciences Holdings Inc (HRMY) has a current valuation score of 8.09, placing it 108th out of 155 in the Pharmaceuticals industry. The company's P/E ratio stands at 14.19, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Zacks.com featured highlights include Harmony Biosciences, Invesco, General Motors, Hewlett Packard and Quanex Building
This Zacks.com article highlights five undervalued price-to-book stocks: Harmony Biosciences, Invesco, General Motors, Hewlett Packard Enterprise, and Quanex Building Products. It explains the P/B ratio as a tool for identifying undervalued stocks, defining book value and its calculation, and discusses the importance of comparing P/B ratios within industries and considering other financial metrics. The article provides a brief profile of each company, including their Zacks Rank, Value Score, and projected EPS growth rates.
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts
Argus has lowered its target price for Harmony Biosciences Holdings Inc (HRMY) to $38.00. The company is a commercial-stage pharmaceutical firm specializing in therapies for rare neurological diseases. The current price of HRMY stock is $35.86.
HRMY|Harmony Biosciences Holdings Inc|Price:35.138|Chg%:-0.722
Harmony Biosciences Holdings Inc (HRMY) shows strong fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. The company's revenue has grown significantly, and it boasts high profit growth and institutional confidence. Analysts have rated the stock as "Buy" with an upside potential, and its stock price is expected to remain stable in the medium term.
BlackRock (HRMY holder) discloses 6.53M Harmony Biosciences shares in 13G/A
BlackRock, Inc. has filed an amended Schedule 13G/A revealing a beneficial ownership of 6,525,663 shares of Harmony Biosciences Holdings, Inc. common stock, which represents an 11.3% stake in the company. BlackRock exercises sole voting power over 6,445,523 shares and sole dispositive power over all 6,525,663 shares. The filing clarifies that while various BlackRock business units hold these shares, no single underlying person possesses more than five percent of Harmony Biosciences' outstanding common stock.
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Harmony Biosciences Holdings, Inc. (HRMY) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2026, with Wall Street anticipating $0.97 EPS and $252.54 million in revenue. The company holds a Zacks Rank of #1 (Strong Buy) and an Earnings ESP of +14.14%, suggesting a high probability of beating the consensus EPS estimate. Investors should monitor the upcoming earnings report, expected around August 4th, as a positive surprise could drive stock appreciation.
Harmony Biosciences Holdings Inc (HRMY) Income Statement
This article provides the quarterly and annual income statements for Harmony Biosciences Holdings Inc (HRMY), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes key financial metrics and answers frequently asked questions about analyzing the company's income statement. The data allows investors to assess HRMY's performance, operational efficiency, and growth trends over various periods.
Harmony Biosciences Holdings Inc
This article provides key financial data for Harmony Biosciences Holdings Inc (HRMY), including its market capitalization of $2.08 billion and a P/E TTM of 14.25. It shows the company's revenue breakdown by region, with $868.45 million from the United States, but notes that detailed breakdowns by business segment and further regional data are not yet disclosed. The stock closed at $36.010, up 1.95%, with after-hours trading mirroring that price.
Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative?
Harmony Biosciences Holdings recently announced the departure of its CFO, Glenn Reicin, and appointed Stephen Mollichella as interim while reiterating its full-year 2026 net product revenue guidance of US$1.00 billion to US$1.04 billion. The company's investment narrative continues to hinge on the success of its WAKIX franchise and emergent neurology pipeline, with revenue execution being the near-term catalyst and WAKIX concentration risk remaining a key concern. Analysts' views vary, with some painting a cautious picture due to WAKIX dependence and patent risk, suggesting potential shifts in outlook after the CFO change.
Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative?
Harmony Biosciences (HRMY) recently announced the departure of its CFO, Glenn Reicin, and the appointment of an interim CFO. Despite this leadership change, the company reaffirmed its full-year 2026 net product revenue guidance of US$1.00 billion to US$1.04 billion, indicating continued confidence in its operations. The article suggests this reaffirms the importance of executing on revenue targets while highlighting the ongoing concentration risk associated with the WAKIX franchise for investors.
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Quest Diagnostics (DGX)
Analysts have issued neutral ratings for Harmony Biosciences Holdings (HRMY) and Quest Diagnostics (DGX), suggesting they are neither strongly bullish nor bearish on the stocks. While Harmony Biosciences received a "Moderate Buy" consensus with a potential 17.9% upside, Quest Diagnostics also secured a "Moderate Buy" with a 6.3% upside from current levels, based on analyst price targets. UBS and Goldman Sachs maintained 'Hold' ratings for Harmony, and UBS and Robert W. Baird maintained 'Hold' ratings for Quest Diagnostics.
HRMY|Harmony Biosciences Holdings Inc|Price:35.780|Chg%:+0.920
Harmony Biosciences Holdings Inc. (HRMY) shows strong fundamentals with high revenue and profit growth, despite its stock trading sideways recently. The company, focused on rare neurological diseases, has a "Buy" rating from analysts with a target price of $44.91, and its valuation is considered fairly valued within the Pharmaceuticals industry. Institutional ownership is high, and the stock is seen as suitable for range-bound swing trading in the medium term.
ETFs Investing in Harmony Biosciences Holdings, Inc. Stocks
This article lists various ETFs that currently hold Harmony Biosciences Holdings, Inc. (HRMY) stocks, providing detailed information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year total return. The ETFs mainly focus on small-cap and healthcare sectors, offering investors diversified exposure to HRMY and similar companies.
